This study examines whether patients treated with specialty pharmaceuticals have improved outcomes compared with patients treated with conventional therapies, and evaluates costs associated with these treatments.
Adam Lustig, MS
Advertisement
Articles by Adam Lustig, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5